| Filed On | Filing |
|---|---|
| 13 Oct 2026 | SCHEDULE 13G |
| 14 Sep 2026 | 144 |
| 14 Sep 2026 |
Form 4: Meeker David P, Director
Received 50,000 shares by exercise or conversion ($303K) · Sold 50,000 shares ($5.13M) |
| 01 Sep 2026 |
Form 4: Smith Hunter C, Chief Financial Officer
Received 57,187 shares by exercise or conversion ($1.47M) · Sold 62,774 shares ($6.62M) |
| 31 Aug 2026 | 144 |
| 18 Aug 2026 |
Form 4: Joshi Manher, Chief Medical Officer
Granted 50,000 Stock Options (Right to Buy) · Granted 25,000 Restricted Stock Units |
| 18 Aug 2026 |
Form 3: Joshi Manher, Chief Medical Officer
No securities owned |
| 17 Aug 2026 |
Form 4: Shulman Joseph, Chief Technical Officer
Received 2,024 shares by exercise or conversion ($13.8K) · Sold 5,079 shares ($608K) |
| 17 Aug 2026 |
Form 4: Garfield Alastair, Chief Scientific Officer
Sold 7,763 shares ($913K) |
| 14 Aug 2026 |
Form 4: Lee Jennifer Kayden, EVP, Head of North America
Received 56,601 shares by exercise or conversion ($997K) · Sold 75,834 shares ($8.9M) |
| 14 Aug 2026 |
Form 4: Mazabraud Yann, EVP, Head of International
Received 46,625 shares by exercise or conversion ($317K) · Sold 57,000 shares ($6.62M) |
| 13 Aug 2026 | 144 |
| 13 Aug 2026 | 144 |
| 13 Aug 2026 | 144 |
| 12 Aug 2026 | 144 |
| 11 Aug 2026 | 144 |
| 10 Aug 2026 | 144 |
| 04 Aug 2026 | 10-Q |
| 04 Aug 2026 | 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more |
| 02 Jul 2026 |
Form 4: Garfield Alastair, Chief Scientific Officer
Received 4,445 shares by exercise or conversion · Gave up 2,150 shares to cover exercise price or tax ($237K) |
Loading...